Company Analysis Fusion Pharmaceuticals Inc.
1. Summary
Advantages
- Price (21.55 $) is less than fair price (24.51 $)
- The stock's return over the last year (0%) is higher than the sector average (-47.29%).
Disadvantages
- Dividends (0%) are below the sector average (0.5339%).
- Current debt level 13.62% has increased over 5 years from 8.21%.
- The company's current efficiency (ROE=-42.65%) is lower than the sector average (ROE=103.63%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Fusion Pharmaceuticals Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 0% | -35.1% | 0.9% |
| 90 days | 0% | -47.8% | 8.1% |
| 1 year | 0% | -47.3% | 19.3% |
FUSN vs Sector: Fusion Pharmaceuticals Inc. has outperformed the "Healthcare" sector by 47.29% over the past year.
FUSN vs Market: Fusion Pharmaceuticals Inc. has significantly underperformed the market by -19.31% over the past year.
Stable price: FUSN is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: FUSN with weekly volatility of 0% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Below fair price: The current price (21.55 $) is lower than the fair price (24.51 $).
Price not significantly lower than the fair price: The current price (21.55 $) is slightly lower than the fair price by 13.7%.
5.2. P/E
P/E vs Sector: The company's P/E (0) is higher than that of the sector as a whole (-274.25).
P/E vs Market: The company's P/E (0) is higher than that of the market as a whole (-80.5).
5.2.1 P/E Similar companies
5.3. P/BV
P/BV vs Sector: The company's P/BV (2.35) is lower than that of the sector as a whole (256.7).
P/BV vs Market: The company's P/BV (2.35) is lower than that of the market as a whole (51.89).
5.3.1 P/BV Similar companies
5.5. P/S
P/S vs Sector: The company's P/S indicator (252.87) is higher than that of the sector as a whole (56.99).
P/S vs Market: The company's P/S indicator (252.87) is higher than that of the market as a whole (137.42).
5.5.1 P/S Similar companies
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-5.22) is lower than that of the sector as a whole (12.51).
EV/Ebitda vs Market: The company's EV/Ebitda (-5.22) is higher than that of the market as a whole (-47.95).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Rising and has grown by 4.33% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (4.33%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-22.73%).
6.4. ROE
ROE vs Sector: The company's ROE (-42.65%) is lower than that of the sector as a whole (103.63%).
ROE vs Market: The company's ROE (-42.65%) is lower than that of the market as a whole (-10.25%).
6.6. ROA
ROA vs Sector: The company's ROA (-33.2%) is lower than that of the sector as a whole (-2.84%).
ROA vs Market: The company's ROA (-33.2%) is lower than that of the market as a whole (39.65%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (-32.78%) is lower than that of the sector as a whole (1.17%).
ROIC vs Market: The company's ROIC (-32.78%) is lower than that of the market as a whole (8.73%).
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5339%.
8.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
8.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
9. Insider trades
9.1. Insider trading
Insider Buying Exceeds insider sales by 100% over the last 3 months.
9.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 21.04.2022 | Valliant John Chief Executive Officer |
Sale | 6.01 | 5 541 | 922 |
| 20.04.2022 | Valliant John Chief Executive Officer |
Sale | 6.02 | 2 209 | 367 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
Based on sources: porti.ru
